세계의 종양학 동반진단 검사 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)
Companion Diagnostic Tests in Oncology Market (Detection Technique: Protein Detection, DNA Detection, and Others; and Biomarker: EGFR, KRAS, HER2, BRAF V600E, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1487557
리서치사:Transparency Market Research
발행일:2024년 04월
페이지 정보:영문 232 Pages
라이선스 & 가격 (부가세 별도)
한글목차
종양학 분야 동반진단 검사 시장 - 조사 범위
TMR의 종양학 분야 동반진단 검사 세계 시장 조사 보고서는 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측연도로 하여 2018년부터 2034년까지 세계 종양학 동반진단 검사 시장의 수익과 예측을 제공합니다. 또한, 2024년부터 2034년까지 세계 동반진단검사 시장의 연평균 성장률(CAGR%)을 제시합니다.
이 보고서는 1차적으로 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체를 인터뷰하고, 2차적으로 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참고하여 종양학 분야의 동반진단 검사 시장을 파악하기 위해 광범위한 조사를 통해 작성되었습니다. 동반진단검사 시장을 파악하기 위해 주요 기업의 제품 자료, 연차보고서, 보도자료, 관련 문서 등을 참고하였습니다.
시장 현황
2023년 시장 규모
61억 달러
2034년 시장 가치
170억 달러
CAGR
9.5%
이 보고서는 종양학 분야의 동반진단검사(Companion Diagnostic Testing in Oncology) 세계 시장 경쟁 구도를 조사했습니다. 종양학 동반 진단 테스트 세계 시장에서 사업을 운영하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되어 있습니다. 기업 개요, 재무 상태, 최근 동향, SWOT는 이 보고서에서 프로파일링된 세계 동반 진단 테스트 시장의 기업 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
서론
시장 개요
시장 역학
세계 시장 분석과 예측, 2020년-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 M&A
COVID-19 팬데믹의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 탐지 기술별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 탐지 기술별, 2020년-2034년
단백질 탐지
면역조직화학
DNA 탐지
중합효소 연쇄반응(PCR)
차세대 시퀸싱(NGS)
In Situ Hybridization
기타
시장의 매력 : 탐지 기술별
제7장 세계 시장 분석과 예측 : 바이오마커별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 바이오마커별, 2020년-2034년
EGFR
KRAS
HER2
BRAF V600E
기타
시장의 매력 : 바이오마커별
제8장 세계 시장 분석과 예측 : 암 유형별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 암 유형별, 2020년-2034년
유방암
폐암
대장암
간암
흑색종
기타
시장의 매력 : 암 유형별
제9장 세계 시장 분석과 예측 : 최종사용자별
서론과 정의
주요 조사 결과/발전
시장 규모 예측 : 최종사용자별, 2020년-2034년
병원
전문 클리닉
진단실험실
기타
시장의 매력 : 최종사용자별
제10장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020년-2034년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제11장 북미 시장 분석과 예측
제12장 유럽 시장 분석과 예측
제13장 아시아태평양 시장 분석과 예측
제14장 라틴아메리카 시장 분석과 예측
제15장 중동 및 아프리카 시장 분석과 예측
제16장 경쟁 구도
시장 경쟁 매트릭스(기업 Tier별, 기업 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Abbott
F. Hoffmann-LA Roche AG
Genomic Health, Inc.
QIAGEN
Agilent Technologies, Inc.
AGENDIA N.V.
bioMerieux SA
Illumina, Inc.
Siemens Healthineers
Thermo Fisher Scientific Inc.
BioGenex
LSH
영문 목차
영문목차
Companion Diagnostic Tests in Oncology Market - Scope of Report
TMR's report on the global companion diagnostic tests in oncology market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global companion diagnostic tests in oncology market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global companion diagnostic tests in oncology market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the companion diagnostic tests in oncology market.
Market Snapshot
Market Value in 2023
US$ 6.1 Bn
Market Value in 2034
US$ 17 Bn
CAGR
9.5%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global companion diagnostic tests in oncology market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global companion diagnostic tests in oncology market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global companion diagnostic tests in oncology market.
The report delves into the competitive landscape of the global companion diagnostic tests in oncology market. Key players operating in the global companion diagnostic tests in oncology market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global companion diagnostic tests in oncology market profiled in this report.
Key Questions Answered in Global companion diagnostic tests in oncology Market Report:
What is the sales/revenue generated by companion diagnostic tests in oncology across all regions during the forecast period?
What are the opportunities in the global companion diagnostic tests in oncology market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Companion Diagnostic Tests in Oncology Market - Research Objectives and Research Approach
The comprehensive report on the global companion diagnostic tests in oncology market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global companion diagnostic tests in oncology market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global companion diagnostic tests in oncology market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Companion Diagnostic Tests in Oncology Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, 2020 - 2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Detection Technique
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Detection Technique, 2020 - 2034
6.3.1. Protein Detection
6.3.1.1. Immunohistochemistry
6.3.2. DNA Detection
6.3.2.1. Polymerase Chain Reaction (PCR)
6.3.2.2. Next-generation Sequencing (NGS)
6.3.2.3. In Situ Hybridization
6.3.3. Others
6.4. Market Attractiveness, by Detection Technique
7. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Biomarker
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Biomarker, 2020 - 2034
7.3.1. EGFR
7.3.2. KRAS
7.3.3. HER2
7.3.4. BRAF V600E
7.3.5. Others
7.3.6. 7.4 Market Attractiveness, by Biomarker
8. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Cancer Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Cancer Type, 2020 - 2034
8.3.1. Breast Cancer
8.3.2. Lung Cancer
8.3.3. Colorectal Cancer
8.3.4. Liver Cancer
8.3.5. Melanoma
8.3.6. Others
8.4. Market Attractiveness, by Cancer Type
9. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020 - 2034
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Diagnostic Labs
9.3.4. Others
9.4. Market Attractiveness, by End-user
10. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020 - 2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Companion Diagnostic Tests in Oncology Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Detection Technique, 2020 - 2034
11.2.1. Protein Detection
11.2.1.1. Immunohistochemistry
11.2.2. DNA Detection
11.2.2.1. Polymerase Chain Reaction (PCR)
11.2.2.2. Next-generation Sequencing (NGS)
11.2.2.3. In Situ Hybridization
11.2.3. Others
11.3. Market Attractiveness, by Detection Technique
11.4. Market Value Forecast, by Biomarker, 2020 - 2034
11.4.1. EGFR
11.4.2. KRAS
11.4.3. HER2
11.4.4. BRAF V600E
11.4.5. Others
11.5. Market Attractiveness, by Biomarker
11.6. Market Value Forecast, by Cancer Type, 2020 - 2034
11.6.1. Breast Cancer
11.6.2. Lung Cancer
11.6.3. Colorectal Cancer
11.6.4. Liver Cancer
11.6.5. Melanoma
11.6.6. Others
11.7. Market Attractiveness, by Cancer Type
11.8. Market Value Forecast, by End-user, 2020 - 2034
11.8.1. Hospitals
11.8.2. Specialty Clinics
11.8.3. Diagnostic Labs
11.8.4. Others
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country, 2020 - 2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Detection Technique
11.11.2. By Biomarker
11.11.3. By Cancer Type
11.11.4. By End-user
11.11.5. By Country
12. Europe Companion Diagnostic Tests in Oncology Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Detection Technique, 2020 - 2034
12.2.1. Protein Detection
12.2.1.1. Immunohistochemistry
12.2.2. DNA Detection
12.2.2.1. Polymerase Chain Reaction (PCR)
12.2.2.2. Next-generation Sequencing (NGS)
12.2.2.3. In Situ Hybridization
12.2.3. Others
12.3. Market Attractiveness, by Detection Technique
12.4. Market Value Forecast, by Biomarker, 2020 - 2034
12.4.1. EGFR
12.4.2. KRAS
12.4.3. HER2
12.4.4. BRAF V600E
12.4.5. Others
12.5. Market Attractiveness, by Biomarker
12.6. Market Value Forecast, by Cancer Type, 2020 - 2034
12.6.1. Breast Cancer
12.6.2. Lung Cancer
12.6.3. Colorectal Cancer
12.6.4. Liver Cancer
12.6.5. Melanoma
12.6.6. Others
12.7. Market Attractiveness, by Cancer Type
12.8. Market Value Forecast, by End-user, 2020 - 2034
12.8.1. Hospitals
12.8.2. Specialty Clinics
12.8.3. Diagnostic Labs
12.8.4. Others
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Detection Technique
12.11.2. By Biomarker
12.11.3. By Cancer Type
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Companion Diagnostic Tests in Oncology Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Detection Technique, 2020 - 2034
13.2.1. Protein Detection
13.2.1.1. Immunohistochemistry
13.2.2. DNA Detection
13.2.2.1. Polymerase Chain Reaction (PCR)
13.2.2.2. Next-generation Sequencing (NGS)
13.2.2.3. In Situ Hybridization
13.2.3. Others
13.3. Market Attractiveness, by Detection Technique
13.4. Market Value Forecast, by Biomarker, 2020 - 2034
13.4.1. EGFR
13.4.2. KRAS
13.4.3. HER2
13.4.4. BRAF V600E
13.4.5. Others
13.5. Market Attractiveness, by Biomarker
13.6. Market Value Forecast, by Cancer Type, 2020 - 2034
13.6.1. Breast Cancer
13.6.2. Lung Cancer
13.6.3. Colorectal Cancer
13.6.4. Liver Cancer
13.6.5. Melanoma
13.6.6. Others
13.7. Market Attractiveness, by Cancer Type
13.8. Market Value Forecast, by End-user, 2020 - 2034
13.8.1. Hospitals
13.8.2. Specialty Clinics
13.8.3. Diagnostic Labs
13.8.4. Others
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Detection Technique
13.11.2. By Biomarker
13.11.3. By Cancer Type
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Companion Diagnostic Tests in Oncology Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Detection Technique, 2020 - 2034
14.2.1. Protein Detection
14.2.1.1. Immunohistochemistry
14.2.2. DNA Detection
14.2.2.1. Polymerase Chain Reaction (PCR)
14.2.2.2. Next-generation Sequencing (NGS)
14.2.2.3. In Situ Hybridization
14.2.3. Others
14.3. Market Attractiveness, by Detection Technique
14.4. Market Value Forecast, by Biomarker, 2020 - 2034
14.4.1. EGFR
14.4.2. KRAS
14.4.3. HER2
14.4.4. BRAF V600E
14.4.5. Others
14.5. Market Attractiveness, by Biomarker
14.6. Market Value Forecast, by Cancer Type, 2020 - 2034
14.6.1. Breast Cancer
14.6.2. Lung Cancer
14.6.3. Colorectal Cancer
14.6.4. Liver Cancer
14.6.5. Melanoma
14.6.6. Others
14.7. Market Attractiveness, by Cancer Type
14.8. Market Value Forecast, by End-user, 2020 - 2034
14.8.1. Hospitals
14.8.2. Specialty Clinics
14.8.3. Diagnostic Labs
14.8.4. Others
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Detection Technique
14.11.2. By Biomarker
14.11.3. By Cancer Type
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Companion Diagnostic Tests in Oncology Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Detection Technique, 2020 - 2034
15.2.1. Protein Detection
15.2.1.1. Immunohistochemistry
15.2.2. DNA Detection
15.2.2.1. Polymerase Chain Reaction (PCR)
15.2.2.2. Next-generation Sequencing (NGS)
15.2.2.3. In Situ Hybridization
15.2.3. Others
15.3. Market Attractiveness, by Detection Technique
15.4. Market Value Forecast, by Biomarker, 2020 - 2034
15.4.1. EGFR
15.4.2. KRAS
15.4.3. HER2
15.4.4. BRAF V600E
15.4.5. Others
15.5. Market Attractiveness, by Biomarker
15.6. Market Value Forecast, by Cancer Type, 2020 - 2034
15.6.1. Breast Cancer
15.6.2. Lung Cancer
15.6.3. Colorectal Cancer
15.6.4. Liver Cancer
15.6.5. Melanoma
15.6.6. Others
15.7. Market Attractiveness, by Cancer Type
15.8. Market Value Forecast, by End-user, 2020 - 2034
15.8.1. Hospitals
15.8.2. Specialty Clinics
15.8.3. Diagnostic Labs
15.8.4. Others
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Detection Technique
15.11.2. By Biomarker
15.11.3. By Cancer Type
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Abbott
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. F. Hoffmann-LA Roche AG
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Genomic Health, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. QIAGEN
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Agilent Technologies, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. AGENDIA N.V.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. bioMerieux SA
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Illumina, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Siemens Healthineers
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Thermo Fisher Scientific Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. BioGenex
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
